Stratification of bipolar disorder by psychotic features and a genome-wide estimate of schizophrenia liability

Judith Allardyce[1] MRCPsych PhD, Ganna Leonenko[1] PhD, Marian Hamshere[1] PhD,

Antonio F. Pardiñas[1] PhD, Liz Forty[1] PhD, Sarah Knott[2] PhD, Katherine-Gordon

Smith[2] PhD, David J. Porteus[3] PhD, Caroline Haywood[3] PhD, Arianna Di Florio[1] MD

PhD, Lisa Jones[2] PhD, Andrew M. McIntosh[3] FRCPsych MD, Michael J. Owen[1]

FRCPsych PhD, Peter Holmans[1] PhD, James T.R. Walters[1] MRCPsych PhD, Nicholas

Craddock[1] FRCPsych PhD, Ian Jones[1] FRCPsych PhD, Michael C. O'Donovan[1]

FRCPsych PhD, Valentina Escott-Price[1] PhD

[1] MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological

Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff,

UK

[2] Department of Psychological Medicine, University of Worcester, Worcester, UK

[3] Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of

Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

Division of Psychiatry, University of Edinburgh, Edinburgh, UK

Correspondence to: Judith Allardyce

MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff University, Hadyn
Ellis Building, Maindy Road, Cathays, Cardiff, CF24 4HQ

+44 (0)29 2068 8320

allardycej2@cardiff.ac.uk

Word count: 2968

Date of revision 19/09/2017

Key Points

Question: what is the relationship between schizophrenia related polygenic liability and the occurrence and level of mood-incongruence of psychotic symptoms in bipolar disorder (BD)?

Findings: in this case-control study including 4436 BD cases, 4976 schizophrenia cases and 9012 controls, there was an exposure-response gradient of polygenic risk: Schizophrenia > BD with prominent mood-incongruent psychotic features > BD with mood-congruent psychotic features > BD with no psychosis, all differential associations were statistically-significant.

Meaning: A gradient of genetic liability across schizophrenia and bipolar disorder, indexed by the occurrence of psychosis and level of mood-incongruence has been shown for the first time.

Abstract

Importance

Bipolar disorder (BD) overlaps schizophrenia in its clinical presentation and genetic liability. Alternative approaches to patient stratification beyond current diagnostic categories are needed to understand the underlying disease processes/mechanisms.

Objectives

To investigate the relationship between common-variant liability for schizophrenia, indexed by polygenic risk scores (PRS) and psychotic presentations of BD, using clinical descriptions which consider both occurrence and level of mood-incongruent psychotic features.

Design

Case-control design: using multinomial logistic regression, to estimate differential associations of PRS across categories of cases and controls.

Settings & Participants

4399 BD cases, 2966 (67%) female, mean age-at-interview 46 [sd 12] years, from the BD Research Network (BDRN) were included in the final analyses. For comparison genotypic data for 4976 schizophrenia cases and 9012 controls from the Type-1 diabetes genetics consortium and Generation Scotland were included.

Exposure

Standardised PRS, calculated using alleles with an association p-value threshold < 0.05 in the second Psychiatric Genomics Consortium genome-wide association study of schizophrenia, adjusted for the first 10 population principal components and genotyping-platform.

Main outcome measure

Multinomial logit models estimated PRS associations with BD stratified by (1) Research Diagnostic Criteria (RDC) BD subtypes (2) Lifetime occurrence of psychosis.(3) Lifetime mood-incongruent psychotic features and (4) ordinal logistic regression examined PRS associations across levels of mood-incongruence. Ratings were derived from the Schedule for Clinical Assessment in Neuropsychiatry interview (SCAN) and the Bipolar Affective Disorder Dimension Scale (BADDS).

Results

Across clinical phenotypes, there was an exposure-response gradient with the strongest PRS association for schizophrenia (RR=1.94, (95% C.I. 1.86, 2.01)), then schizoaffective BD (RR=1.37, (95% C.I. 1.22, 1.54)), BD I (RR= 1.30, (95% C.I. 1.24, 1.36)) and BD II (RR=1.04, (95% C.I. 0.97, 1.11)). Within BD cases, there was an effect gradient, indexed by the nature of psychosis, with prominent mood-incongruent psychotic features having the strongest association (RR=1.46, (95% C.I. 1.36, 1.57)), followed by mood-congruent psychosis (RR= 1.24, (95% C.I. 1.17, 1.33)) and lastly, BD cases with no history of psychosis (RR=1.09, (95% C.I. 1.04, 1.15)).

Conclusion

We show for the first time a polygenic-risk gradient, across schizophrenia and bipolar disorder, indexed by the occurrence and level of mood-incongruent psychotic symptoms.

Introduction

Although classified as a discrete diagnostic category[1-3], bipolar disorder (BD) overlaps considerably with schizophrenia (SCZ) in both its clinical presentation [4-13] and genetic liability [14-22]. BD is a phenomenologically heterogeneous construct and within the diagnostic category, individuals may have quite different symptom profiles. It has been proposed, that this clinical heterogeneity indicates underlying aetiological heterogeneity and the degree of clinical similarity between BD and SCZ reflects, overlapping alleles which selectively influence specific, shared clinical characteristics, rather than the global risk for the disorders [23-25].

Delusions and hallucinations are common in BD [26,27] with around one third of all psychotic features judged to be mood-incongruent [28,29]. Mood-incongruent psychotic features, are associated with poorer prognosis, poor lithium-response and are qualitatively similar to the prototypic symptoms of SCZ [30-32], suggesting that BD with psychosis and particularly mood-incongruent psychotic features, may specify a subgroup/stratum with stronger aetiological links to SCZ. Stratified linkage and candidate-gene studies of BD associations with chromosomal regions and genes implicated in SCZ, show stronger effects in psychosis and mood-incongruent subsamples [33-36] providing some support for this causal heterogeneity hypothesis, however lack of consistency in earlier linkage and candidate-gene studies renders the overall support weak.

Recently, genome-wide association studies (GWAS) have found a substantial polygenic component to both BD and SCZ risk, with a large proportion of their genetic variance explained by common alleles, partially shared across the two disorders [20]. Polygenic-risk can be calculated for individuals, with a single summary measure: the polygenic risk score (PRS), which allows us to examine the genetic basis of symptom domains, within

107 and across the two disorders [37-39] with greater power than the historical linkage and

108 candidate-gene approaches. PRS-SCZ differentiate BD from controls [20,40] and there are

109 differential associations across subtypes with schizoaffective bipolar disorder (SABD)

110 (intermediate subtype, characterised by admixture of SCZ and BD symptoms) having a

111 relatively larger burden of SCZ risk, compared to other BD subtypes [15,41]. To date, lack of

112 power in well phenotyped samples has hindered fine-scale examination of the

113 relationship between SCZ polygenic-risk and psychotic symptoms in BD.

114 We aimed to examine the relationship between polygenic liability for SCZ and psychotic

115 presentations of BD using PRS generated from the most powerful SCZ-GWAS discovery

116 set available, currently [21]. Measures relevant to the occurrence and nature of psychotic

117 symptoms were considered. We hypothesised BD with psychosis would be associated

118 with higher polygenic-risk for SCZ and this association would be stronger when mood-

119 incongruent psychotic features were present, given their phenotypic similarity to the

120 psychotic symptoms of prototypic SCZ.

Methods

Sample Ascertainment

Bipolar Disorder sample

124 4436 cases of BD with deep phenotypic information, European ancestry, domicile in the

125 UK, collected between 2000 - 2013 were available via the UK BD Research Network

126 (BDRN) using recruitment methods reported previously [15,42,43]. The sample has 1399

127 cases not included in prior BDRN publications [15,41]. All participants were assessed using

128 a consistent protocol which included the Schedule for Clinical Assessment in

129 Neuropsychiatry interview (SCAN) [44] administered by trained research psychologists and

130 psychiatrists, with very good to excellent inter-rater reliability for all domains of

131   psychopathology [45]. Using information from the SCAN and casenote review, the

132   Operational Criteria Checklist (OPCRIT) [46] was completed. Research Diagnostic

133   Criteria (RDC) [3]diagnoses, which differentiate individuals on the basis of the their

134   pattern of mood and psychotic symptoms better [41] than either DSM [2] or ICD–10[1], were

135   made using the consensus lifetime best-estimate method, informed by all available

136   information[47].

Schizophrenia sample

138   To allow comparison of BD with SCZ, we included a subset (N=4976) of the CLOZUK

139   sample, collected via the Zapronex® Treatment Access System as detailed in a previous

140   report[48], All were prescribed clozapine for treatment resistant SCZ (TRS) and are

141   independent of, and unrelated (pi-hat <0.2) to individuals in the discovery GWAS[21]. In

142   principle, TRS may carry higher polygenic-risk burden, however PRS in CLOZUK are

143   similar to the other SCZ samples used by the Psychiatric Genomics Consortium[21].

Control Samples

145   The controls came from two UK sources: the Type-1 diabetes genetics consortium

146   (TIDGC) (n = 2,532) are unscreened controls, recruited through the 1958 birth-cohort [49]

147   and the other is a subsample of the Generation Scotland (n = 6,480) study, screened for

148   psychiatric disorders [50]. Controls are unrelated (pi-hat < 0.2) to individuals in the PGC-

149   SCZ discovery set, and were matched ancestrally to our case datasets [48].

150   All samples have appropriate ethics approvals.

Genotyping, quality control (QC), phasing and imputation

Bipolar cases

153   Genotypic data for the BD cases were processed in 3 batches, each on a different

154   platform. To mitigate against potential bias from batch effects[51], stringent QC was

155   performed on each platform separately prior to merging. Single nucleotide

156   polymorphisms (SNPs) were excluded if the call rate was < 98%, MAF was < 0.01 or

157   they deviated from HWE at $p < 1\times10^{-6}$. Individuals were excluded if they had minimal or

158   excessive autosomal homozygosity ($|F|>0.1$), high pairwise relatedness (pi-hat > 0.2) or

159   mismatch between recorded and genotypic sex. Following QC, the data for each

160   platform were phased using SHAPEIT [52] and imputed with IMPUTE2 [53], using the 1000

161   Genomes reference panel (Phase3, 2014). Imputed data were converted into the most

162   probable genotypes (probability >0.9) and merged on shared SNPs. 4399 BD cases

163   remained after QC.

164   CLOZUK cases and Controls

165   The CLOZUK and control samples had been though strict QC separately, before being

166   phased and imputed simultaneously as part of a larger SCZ study [48].

167   Merging BD, CLOZUK and control imputed genotypic datasets

168   After excluding SNPs with stand ambiguity; BD, CLOZUK and control samples were

169   merged and the imputed markers underwent a second QC filter[51], excluding SNPs with;

170   missingness in >5% of individuals, (INFO) <0.8, MAF <0.01 or deviation from HWE at

171   $p < 1\times10^{-6}$.

172   Principal Component Analysis

173   To adjust for potential confounding from population structure, we performed PCA using

174   PLINK v1.9, after LD pruning and frequency filtering the SNPs from the merged

175   sample, keeping the eigenvectors for the first 10 principal components (PCs) to use as

176   covariates in the association analysis.

Polygenic Risk Scores (PRS)

We generated PRS[20], using the 2014 PGC-SCZ meta-analysis as our discovery set[21] calculated for each individual, based on a set of alleles with association p-values < 0.05. This decision was informed by the PGC leave one-cohort-out PRS analyses, for all SNP selection p-value thresholds, which found the median and mode of the cut-off = 0.05. This represents the association that best optimises the balance of false and true risk alleles, at the current discovery sample size [21]. The most informative and independent markers were selected to minimise statistical noise where possible, using p-value informed clumping, at r^2 <0.2 with 1MB windows and by excluding the extended MHC (Chr6: position 25-35MB) because of its complex LD structure .

Outcome measure of lifetime psychosis & mood incongruence

Subtypes of BD

RDC subtypes were used as categorical outcomes in case-control analyses. The RDC [3] and Diagnostic and Statistical Manual of Mental Disorders (DSM) [2], though not the ICD-10 Classification of Mental and Behavioural Disorder (ICD-10) [1], subdivides BD into bipolar I disorder (BD I) and bipolar II disorder (BD II) depending on the nature of the mood states; mania in (BP I) and hypomania in (BP II). All classification systems recognise SABD. Psychotic symptoms are most prominent in SABD, then BD I, and least prominent in BD II [54,55].

The Bipolar Affective Disorder Dimension Scale

Outcome measures were generated from The Bipolar Affective Disorder Scale (BADDS) Psychosis (P) and mood-incongruence (I) subscales, which provide an ordered (not necessarily linear) measure of lifetime symptom domain severity[56]. An inter-rater

reliability exercise for this sample demonstrates excellent interclass correlation: (P) 0.91 and (I) 0.89.

1) A binary categorical outcome measure for lifetime occurrence of psychosis defined as an unambiguous episode of positive and/or disorganised psychotic symptoms, generated by dichotomising the (P) domain scale at a score > 9 [56].

2) A binary categorical outcome measure for lifetime occurrence of predominant mood-incongruent psychotic features (high v low prominence of mood-incongruence), generated by dichotomising the (I) domain scale at a score >19.

3) An ordinal measure of mood-incongruent psychotic features which assesses the overall balance between mood-congruent and mood-incongruent psychosis across the lifetime, rated using all available information according to BDRN protocol (E supplement : Note 1)

Statistical Analysis

A multinomial logit model (MNLM) was used to estimate differential associations of standardised PRS, adjusted for the first 10 PCs and genotyping-platform, across categories of cases and controls. We report the estimated coefficients transformed to relative risk-ratios (RR), defined as the exponentiated regression coefficient. PRS association across levels of mood-incongruent psychotic features using ordinal logistic regression was also estimated. To examine whether SABD subtypes were driving observed PRS associations with mood-incongruent psychotic features, we did a sensitivity analysis excluding SABD cases. Post-estimation predicted probabilities were plotted to aid interpretation of the PRS associations across RDC subtypes of BD [57]. To correct for multiple comparisons of PRS associations across different phenotypic strata within each model, bootstrapped standard errors and 95% confidence intervals were

224 generated, as an approximation to exact permutation methods [58](supplementary E - Note

225 2). Possible family-wise type-1 error proliferation was controlled for using the Bonferroni

226 Method, calculated by multiplying the bootstrapped p-values by four [59].

227 Post-hoc analyses used a MNLM case-control design to examine differential associations

228 across composite phenotypic categories defined by subtype BDI and BD II stratified by

229 psychosis status and a complementary logistic regression analyses comparing the effect

230 of PRS on lifetime occurrence of psychosis, across BD I and BD II subtypes. To examine

231 the distribution of RDC defined cases across levels of PRS, we converted PRS to deciles

232 and generated a stacked bar-chart (SCZ (CLOZUK), SABD, BD I, BD II), by decile.

233 Analyses were performed using PLINK v1.9 [60] or STATA (*Stata Statistical Software:*

234 *Release 14.* College Station, TX: Stata Corp, LP).

Results

Sample description, Genotyping and quality control

237 After merging BD, CLOZUK and control imputed-genotyped samples and further QC,

238 18,387 cases and controls (E-supplementary Table 1) with 3,451,354 SNPs with INFO

239 score > 0.8 and MAF >1% were available for analysis. Within the BD sample 52% (N =

240 2296) of cases endorsed lifetime occurrence of definite psychosis, with <1% missingness

241 in this variable (N=25). Of the BD cases with definite psychosis, 43% (N= 981) were

242 classed as having high lifetime mood-incongruent psychotic features. There was a 9%

243 (N=214) missingness rate for the mood-incongruence variable, within the BD cases with

244 psychosis.

Case Control PRS associations

As expected (Table 1 Section A), PRS discriminated CLOZUK from controls. PRS in those with a diagnosis of SABD or BD I, but not BD II, were significantly higher than controls.

PRS associations within cases

PRS discriminated SCZ from all BD subtypes (Table 2). Within BD, PRS discriminates BD II from both BD I and SABD (Figure 1). The percentage of CLOZUK cases increased monotonically with increasing decile PRS, while the percentage of bipolar subtypes decreased (Figure 2).

PRS associations with psychotic BD

Compared to controls, the PRS were higher in BD, regardless of whether there was a history of psychosis (Table 1, Section B, Figure 2). However, PRS were significantly higher in BD with psychosis, compared to BD without psychosis (Table 1, Section B, figure 3). Within BD cases, PRS discriminated those with and without psychosis (RR=1.25, 95% bootstrapped adjusted p-value < 001, C.I. (1.16, 1.33)).

Post hoc analyses showed the association between PRS and psychosis was present in BD I (OR = 1.21, 95% C.I. 1.10, 1.32) but were not statistically significant in BD II (OR = 0.98, 95% C.I. 0.80, 1.18). Composite subgroup defined as BD I with psychosis - had higher PRS compared to controls (RR = 1.38, 95% C.I. 1.31, 1.46) this association was significantly stronger than that of the composite BD I/no psychosis (RR= 1.16, 95% C.I. 1.08, 1.25). Within BD II, there was no differential association across subgroups defined by presence/absence of psychosis as compared to controls (supplementary-E: Table-1).

PRS associations with mood-incongruent psychotic features

Psychotic BD characterised by high mood-incongruence has a higher SCZ polygenic risk burden than controls, with a one standard-deviation increase in PRS increasing the RR of being in the high mood-incongruence category by 46% (RR= 1.46, bootstrapped, 95% C.I. 1.36, 1.57) (Figure 3, Table 1 Section C). Although the association was significantly weaker than for the high mood-incongruent group, schizophrenia risk-alleles were enriched in those with low mood-incongruence compared with controls (RR= 1.24, bootstrapped 95% C.I. (1.17, 1.33). Sensitivity analysis excluding the SABD group from analyses found comparable results (Table 1: Section D). Finally, a within-BD-case analysis, measuring mood-incongruence on an ordinal scale found the odds of having higher levels of mood-incongruence, increased with increasing PRS (OR=1.17, (bootstrapped p-value < .001, 95% C.I. 1.08 - 1.27)). Analyses excluding the SABD sample found comparable results (OR=1.20, bootstrapped p-value < .001, 95% C.I. 1.09, 1.32).

Discussion

Main Findings

Higher PRS-SCZ in BD [20,61] is well established. Here, we replicate and extend this observation, demonstrating a gradient of PRS associations across SCZ and BD subtypes (CLOZUK > SABD > BD I with psychosis > BD I without psychosis > BD II). We also show BD cases with psychosis carry a higher burden of SCZ risk-alleles, compared to BD without a history of psychosis. Furthermore, individuals with psychotic BD characterised by prominent mood-incongruent psychotic features, carry the highest burden of schizophrenia risk-alleles. There is a clear exposure-response gradient, with increasing PRS associated with psychotic BD and increasing mood-incongruence (mood-

incongruent > mood-congruent > no psychosis), supporting our hypothesis that mood-incongruence indexes phenotypic features linked to SCZ liability.

Previously published work examining PRS for SCZ across BD, stratified by psychosis, did not find significant discrimination [41,62] although a trend was observed, consistent with the findings presented here. The most likely explanations for the enhanced signal in the current analysis are: PRS were constructed using alleles derived from a larger SCZ-GWAS discovery set which reduces measurement error plus improved power from both this and the larger BD sample [63]. This group has shown[41], PRS-SCZ significantly differentiate SABD from non-SABD subtypes, while finding no statistically significant differential between BD stratified by psychosis, suggesting it is the nature of the psychotic symptoms rather than their presence which better indexes liability shared with SCZ. The current analysis supports this proposition that it is the level of mood-incongruence rather than the presence of psychosis *per se* which better specifies a shared biologically-validated dimensional trait, captured, but with less precision by the SABD diagnostic category.

Psychosis and mood-incongruent psychotic features are known to be correlated to poorer prognosis and treatment response[30-32] It is possible the trans-diagnostic exposure-response gradient for PRS with the occurrence and nature of psychotic symptoms presented here, could be the result of a general psychopathological factor cutting across psychiatric disorders which influences the severity of psychopathology generally, as well as, or rather than a psychosis-specific domain and that PRS derived from SCZ GWAS may be indexing a general liability for psychopathology severity (at least in part)[64] rather than a (SCZ) disease specific liability.

Implications

Our study supports the hypothesis that within BD, positive and disorganized psychotic symptoms, and in particular mood-incongruent psychotic features, represent a dimensionally defined stratum with underpinning biological validity. These features are not only phenotypically similar to those observed in prototypal schizophrenia but also index a greater shared genetic aetiology suggesting they share more pathophysiology [65]. It is notable that in those diagnosed with BD I with no history of psychosis, the association with schizophrenia liability was weaker but still on average higher than in the control group, while in the BD II subsample there was no overlap with SCZ liability. We are not suggesting psychotic features are the best or only index of shared pathophysiology, but having established stronger genetic links between the risk for SCZ and BD characterised by the occurrence of psychosis and level of mood-incongruence, we now have a basis to refine this signal. These findings represent a step towards the goal of reconceptualising phenotypic definitions using richer clinical signatures, measured across quantitative/qualitative domains including, symptom loadings and biomarker expression, outlined in the rationale for the Research Domain Criteria (RDoC) [66,67] and the road map for mental health research (ROAMER) [68] projects. It is probable however a multidimensional stratification process will harness the observed clinical heterogeneity better and define more precise patient-strata/subgroups in closer alignment with the underlying pathophysiology [68-70]

Methodological considerations

The phenotypic ratings used in the current analyses are based on both SCAN interviews and case-note review by raters with excellent inter-rater reliability, which is expected to minimise rates of missing data and reduce the likelihood of phenotypic misclassification[71]. Our psychosis phenotypes are broadly defined and likely to represent

imperfect measurements of a continuously distributed phenotype[72], imposing categorical

constraints as we have done may reduce power. We generated PRS using a single

discovery set p-value threshold < 0.05 and dealt with multiple comparisons, across

different phenotypic categories/strata using bootstrap re-sampling approaches within

each of our 4 independent analyses, adjusting for family-wise type-1 error proliferation

using Bonferroni's correction. We have mitigated against potential confounding due to

population stratification and potential batch effects across cases and controls, by

partialling out the first 10 PCs and genotyping platforms from the PRS. The PRS were

generated using most probable genotypes which can potentially reduce power due to a

small (non-differential) loss of information at some markers making our results

conservative, but the conclusions are unlikely to change. Finally, we have only examined

the effect of common variants, as rare variants are not captured by current GWAS.

Conclusions

We show for the first time a gradient of polygenic liability across schizophrenia and

bipolar disorder, indexed by the occurrence and level of mood-incongruence of positive

and disorganised psychotic symptoms. This highlights the usefulness of genetic data to

dissect clinical heterogeneity within and across disorders, and suggests further research

could potentially aid in defining patient stratifiers with improved biological

precision/validity, moving us tentatively towards precision medicine in psychiatry.

407 Reference List

408 1. *ICD-10 Classification of Mental and Behavioural Disorder:Clinical Descriptions and Diagnostic*
409 *Guidelines.* Geneva: World Health Organisation 1992.
410 2. *Diagnostic and Statistical Manual of Mental Disorders* 5th ed. Arlington: American
411 Psychiatric Association; 2013.
412 3. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability.
413 *Archives of general psychiatry.* 1978;35(6):773-782.
414 4. Allardyce J, McCreadie RG, Morrison G, van Os J. Do symptom dimensions or categorical
415 diagnoses best discriminate between known risk factors for psychosis? *Social psychiatry and*
416 *psychiatric epidemiology.* 2007;42(6):429-437.
417 5. Derks EM, Allardyce J, Boks MP, Vermunt JK, Hijman R, Ophoff RA. Kraepelin was right: a
418 latent class analysis of symptom dimensions in patients and controls. *Schizophrenia bulletin.*
419 2012;38(3):495-505.
420 6. Dikeos DG, Wickham H, McDONALD C, et al. Distribution of symptom dimensions across
421 Kraepelinian divisions. *The British Journal of Psychiatry.* 2006;189(4):346-353.
422 7. Kitamura T, Okazaki Y, Fujinawa A, Yoshino M, Kasahara Y. Symptoms of psychoses. A factor-
423 analytic study. *The British Journal of Psychiatry.* 1995;166(2):236-240.
424 8. Lindenmayer J-P, Brown E, Baker RW, et al. An excitement subscale of the Positive and
425 Negative Syndrome Scale. *Schizophrenia research.* 2004;68(2):331-337.
426 9. McGorry P, Bell R, Dudgeon P, Jackson H. The dimensional structure of first episode
427 psychosis: an exploratory factor analysis. *Psychological medicine.* 1998;28(04):935-947.
428 10. McIntosh A, Forrester A, Lawrie S, et al. A factor model of the functional psychoses and the
429 relationship of factors to clinical variables and brain morphology. *Psychological medicine.*
430 2001;31(01):159-171.
431 11. Murray V, McKee I, Miller P, et al. Dimensions and classes of psychosis in a population
432 cohort: a four-class, four-dimension model of schizophrenia and affective psychoses.
433 *Psychological medicine.* 2005;35(04):499-510.
434 12. Ratakonda S, Gorman JM, Yale SA, Amador XF. Characterization of psychotic conditions: Use
435 of the domains of psychopathology model. *Archives of General Psychiatry.* 1998;55(1):75-81.
436 13. Serretti A, Olgiati P. Dimensions of major psychoses: a confirmatory factor analysis of six
437 competing models. *Psychiatry research.* 2004;127(1):101-109.
438 14. Alastair G. Cardno, Frühling V. Rijsdijk, Pak C. Sham, Robin M. Murray, Peter McGuffin. A
439 Twin Study of Genetic Relationships Between Psychotic Symptoms. *American Journal of*
440 *Psychiatry.* 2002;159(4):539-545.
441 15. Charney AW, Ruderfer DM, Stahl EA, et al. Evidence for genetic heterogeneity between
442 clinical subtypes of bipolar disorder. *Transl Psychiatry.* 2017;7:e993.
443 16. Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH. Genetic relationship between
444 five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet.* 2013;45:984-994.
445 17. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF. Common genetic
446 determinants of schizophrenia and bipolar disorder in Swedish families: a population-based
447 study. *Lancet.* 2009;373:234-239.
448 18. Maier W, Lichtermann D, Franke P, Heun R, Falkai P, Rietschel M. The dichotomy of
449 schizophrenia and affective disorders in extended pedigrees. *Schizophrenia*
450 *Research.*57(2):259-266.
451 19. Mortensen P, Pedersen CB, Melbye MM, Mors OO, Ewald HH. Individual and familial risk
452 factors for bipolar affective disorders in denmark. *Archives of General Psychiatry.*
453 2003;60(12):1209-1215.
454 20. Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of
455 schizophrenia and bipolar disorder. *Nature.* 2009;460(7256):748-752.

456   21.   Consortium SWGotPG. Biological insights from 108 schizophrenia-associated genetic loci.
457   *Nature.* 2014;511:421-427.
458   22.   Ruderfer D, Fanous A, Ripke S, McQuillin A, Amdur R. Cross-Disorder Working Group of
459   Psychiatric Genomics Consortium, et al. Polygenic dissection of diagnosis and clinical
460   dimensions of bipolar disorder and schizophrenia. *Mol Psychiatry.* 2014;19(9):1017-1024.
461   23.   Ford JM, Morris SE, Hoffman RE, et al. Studying hallucinations within the NIMH RDoC
462   framework. *Schizophrenia bulletin.* 2014:sbu011.
463   24.   Manchia M, Cullis J, Turecki G, Rouleau GA, Uher R, Alda M. The impact of phenotypic and
464   genetic heterogeneity on results of genome wide association studies of complex diseases.
465   *PloS one.* 2013;8(10):e76295.
466   25.   Wray NR, Maier R. Genetic basis of complex genetic disease: the contribution of disease
467   heterogeneity to missing heritability. *Current Epidemiology Reports.* 2014;1(4):220-227.
468   26.   Diefendorf AR, Kraepelin E. Clinical psychiatry: A textbook for students and physicians,
469   abstracted and adapted from the 7th German edition of Kraepelin's Lehrbuch der Psychiatrie
470   In:1907:562.
471   27.   Organization WH. Report of the international pilot study of schizophrenia. 1973.
472   28.   Azorin JM, Akiskal H, Hantouche E. The mood-instability hypothesis in the origin of mood-
473   congruent versus mood-incongruent psychotic distinction in mania: validation in a French
474   National Study of 1090 patients. *Journal of affective disorders.* 2006;96(3):215-223.
475   29.   Black DW, Nasrallah A. Hallucinations and delusions in 1,715 patients with unipolar and
476   bipolar affective disorders. *Psychopathology.* 1989;22(1):28-34.
477   30.   Goes FS, Zandi PP, Miao K, et al. Mood-incongruent psychotic features in bipolar disorder:
478   familial aggregation and suggestive linkage to 2p11-q14 and 13q21-33. *American Journal of
479   Psychiatry.* 2007;164(2):236-247.
480   31.   Tohen M, Tsuang MT, Goodwin DC. Prediction of outcome in mania by mood-congruent or
481   mood-incongruent psychotic features. *American Journal of Psychiatry.* 1992;149:1580-1580.
482   32.   Toni C, Perugi G, Mata B, Madaro D, Maremmani I, Akiskal HS. Is mood-incongruent manic
483   psychosis a distinct subtype? *European archives of psychiatry and clinical neuroscience.*
484   2001;251(1):12-17.
485   33.   Green EK, Raybould R, Macgregor S, et al. Operation of the schizophrenia susceptibility gene,
486   neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder.
487   *Archives of General Psychiatry.* 2005;62(6):642-648.
488   34.   Park N, Juo SH, Cheng R, et al. Linkage analysis of psychosis in bipolar pedigrees suggests
489   novel putative loci for bipolar disorder and shared susceptibility with schizophrenia. *Mol
490   Psychiatry.* 2004;9(12):1091-1099.
491   35.   Potash JB, Zandi PP, Willour VL, et al. Suggestive linkage to chromosomal regions 13q31 and
492   22q12 in families with psychotic bipolar disorder. *American Journal of Psychiatry.*
493   2003;160(4):680-686.
494   36.   Raybould R, Green EK, MacGregor S, et al. Bipolar disorder and polymorphisms in the
495   dysbindin gene (DTNBP1). *Biological psychiatry.* 2005;57(7):696-701.
496   37.   Dudbridge F. Polygenic Epidemiology. *Genetic Epidemiology.* 2016;40(4):268-272.
497   38.   Pasaniuc B, Price AL. Dissecting the genetics of complex traits using summary association
498   statistics. *Nature Reviews Genetics.* 2016.
499   39.   Wray NR, Lee SH, Mehta D, Vinkhuyzen AA, Dudbridge F, Middeldorp CM. Research review:
500   Polygenic methods and their application to psychiatric traits. *Journal of child psychology and
501   psychiatry, and allied disciplines.* 2014;55(10):1068-1087.
502   40.   Consortium C-DGotPG. Genetic relationship between five psychiatric disorders estimated
503   from genome-wide SNPs. *Nature genetics.* 2013;45(9):984-994.
504   41.   Hamshere ML, O'Donovan MC, Jones IR, et al. Polygenic dissection of the bipolar phenotype.
505   *The British Journal of Psychiatry.* 2011;198(4):284-288.

506 42. Green EK, Hamshere M, Forty L, Gordon-Smith K, Fraser C, Russell E. Replication of bipolar
507   disorder susceptibility alleles and identification of two novel genome-wide significant
508   associations in a new bipolar disorder case-control sample. *Mol Psychiatry.* 2013;18:1302-
509   1307.
510 43. Green EK, Rees E, Walters JTR, et al. Copy number variation in bipolar disorder. *Mol
511   Psychiatry.* 2016;21(1):89-93.
512 44. Wing JK, Babor TT, Brugha TT, et al. Scan: Schedules fonr clinical assessment in
513   neuropsychiatry. *Archives of General Psychiatry.* 1990;47(6):589-593.
514 45. Jones L, Scott J, Haque S, et al. Cognitive style in bipolar disorder. *The British Journal of
515   Psychiatry.* 2005;187(5):431-437.
516 46. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies
517   of psychotic illness: Development and reliability of the opcrit system. *Archives of General
518   Psychiatry.* 1991;48(8):764-770.
519 47. Leckman JF, Sholomskas D, Thompson D, Belanger A, Weissman MM. Best estimate of
520   lifetime psychiatric diagnosis: a methodological study. *Archives of General Psychiatry.*
521   1982;39(8):879-883.
522 48. Pardiñas AF, Holmans P, Pocklington AJ, et al. Common schizophrenia alleles are enriched in
523   mutation-intolerant genes and maintained by background selection. *bioRxiv.* 2016.
524 49. Hilner JE, Perdue LH, Sides EG, et al. Designing and implementing sample and data collection
525   for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC).
526   *Clinical trials.* 2010;7(1_suppl):S5-S32.
527 50. Amador C, Huffman J, Trochet H, et al. Recent genomic heritage in Scotland. *BMC genomics.*
528   2015;16(1):437.
529 51. Zuvich RL, Armstrong LL, Bielinski SJ, et al. Pitfalls of merging GWAS data: lessons learned in
530   the eMERGE network and quality control procedures to maintain high data quality. *Genetic
531   epidemiology.* 2011;35(8):887-898.
532 52. Delaneau O, Zagury J-F, Marchini J. Improved whole-chromosome phasing for disease and
533   population genetic studies. *Nature methods.* 2013;10(1):5-6.
534 53. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype
535   imputation in genome-wide association studies through pre-phasing. *Nature genetics.*
536   2012;44(8):955-959.
537 54. McClellan J, McCurry C. Early onset psychotic disorders: diagnostic stability and clinical
538   characteristics. *European child & adolescent psychiatry.* 1999;8(1):S13-S19.
539 55. Vieta E, Gasto C, Otero A, Nieto E, Vallejo J. Differential features between bipolar I and
540   bipolar II disorder. *Comprehensive psychiatry.* 1997;38(2):98-101.
541 56. Craddock N, Jones I, Kirov G, Jones L. The Bipolar Affective Disorder Dimension Scale
542   (BADDS)–a dimensional scale for rating lifetime psychopathology in bipolar spectrum
543   disorders. *BMC psychiatry.* 2004;4(1):19.
544 57. Scott-Long JFJ. Models for nominal outcomes with case-specific data. In: *Regression Models
545   for Categorical Dependent Variables Using STATA.* Texas 77845: Stata Press; 2006:252-254.
546 58. Westfall PHY, S.S,. *Resampling-based multiple testing: examples and methods for p-value
547   adjustment.* New Jersey: John Wiley & Sons; 1993.
548 59. Large-scale genome-wide association analysis of bipolar disorder identifies a new
549   susceptibility locus near ODZ4. *Nat Genet.* 2011;43:977-983.
550 60. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising
551   to the challenge of larger and richer datasets. *Gigascience.* 2015;4(1):7.
552 61. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with
553   shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet.*
554   2013;381:1371-1379.

555   62.   Ruderfer DM, Fanous AH, Ripke S, McQuillin A, Amdur RL. Polygenic dissection of diagnosis
556   and clinical dimensions of bipolar disorder and schizophrenia. *Mol Psychiatry.* 2014;19:1017-
557   1024.
558   63.   Dudbridge F. Power and predictive accuracy of polygenic risk scores. *PLoS Genet.*
559   2013;9(3):e1003348.
560   64.   Caspi A, Houts RM, Belsky DW, et al. The p Factor: One General Psychopathology Factor in
561   the Structure of Psychiatric Disorders? *Clinical psychological science : a journal of the*
562   *Association for Psychological Science.* 2014;2(2):119-137.
563   65.   Keshavan MS, Morris DW, Sweeney JA, et al. A dimensional approach to the psychosis
564   spectrum between bipolar disorder and schizophrenia: the Schizo-Bipolar Scale.
565   *Schizophrenia research.* 2011;133(1):250-254.
566   66.   Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new
567   classification framework for research on mental disorders. In: Am Psychiatric Assoc; 2010.
568   67.   Insel TR. The NIMH research domain criteria (RDoC) project: precision medicine for
569   psychiatry. *American Journal of Psychiatry.* 2014;171(4):395-397.
570   68.   Schumann G, Binder EB, Holte A, et al. Stratified medicine for mental disorders. *European*
571   *Neuropsychopharmacology.* 2014;24(1):5-50.
572   69.   Insel TR, Cuthbert BN. Brain disorders? Precisely. *Science.* 2015;348(6234):499-500.
573   70.   Joyce DW, Kehagia AA, Tracy DK, Proctor J, Shergill SS. Realising stratified psychiatry using
574   multidimensional signatures and trajectories. *Journal of Translational Medicine.*
575   2017;15(1):15.
576   71.   Allardyce J, Morrison G, Van Os J, Kelly J, Murray RM, McCreadie RG. Schizophrenia is not
577   disappearing in south-west Scotland. *The British journal of psychiatry : the journal of mental*
578   *science.* 2000;177:38-41.
579   72.   Van Os J, Linscott RJ, Myin-Germeys I, Delespaul P, Krabbendam L. A systematic review and
580   meta-analysis of the psychosis continuum: evidence for a psychosis proneness–persistence–
581   impairment model of psychotic disorder. *Psychological medicine.* 2009;39(02):179-195.

582

Table 1:Differential Association of PRS across variously defined BD strata (controls as comparator category)

	N (subsample)	RR	Bootstrapped p-value	Bonferroni Corrected p-value	Bootstrapped 95% confidence intervals
CLOZUK	4,976	1.94	< .001	< .001	1.86, 2.01
		A) Bipolar Disorder cases stratified by RDC defined subtypes			
SABD	356	1.37	< .001	< .001	1.22, 1.54
BD I	2,775	1.30	< .001	< .001	1.24. 1.36
BD II	1,268	1.04	0.26	0.26	0.97, 1.11
		B) Bipolar Disorder cases stratified by lifetime occurrence of psychosis			
No LEP	2,079	1.09	0.001	0.004	1.04, 1.15
LEP	2,296	1.36	< .001	< .001	1.29, 1.43
		C) Psychotic Bipolar Disorder cases stratified by level of mood incongruence			
Low LMI	1,126	1.24	< .001	< .001	1.17, 1.33
High LMI	981	1.46	< .001	< .001	1.36, 1.57
		D) Sensitivity Analysis: Psychotic Bipolar Disorder cases stratified by levels of mood incongruence (excluding SABD cases)			
Low LMI	1,068	1.25	< .001	< .001	1.16, 1.33
High LMI	699	1.49	< .001	< .001	1.37, 1.62

CLOZUK – Treatment resistant Schizophrenia, treated with clozapine, BD I - RDC bipolar disorder subtype I, BD II - RDC bipolar disorder type II, SABD-RDC bipolar schizoaffective disorder, LEP – lifetime ever occurrence of psychotic symptoms, LMI – lifetime pattern of low/high mood incongruent psychotic features RR – relative risk ratio PRS adjusted for 1st 10 PCs and genotyping platform

Table 2: PRS-SCZ associations among cases

	RR	Bootstrapped p-value	Bonferroni corrected p-value	Bootstrapped 95% C.I.
SABD compared to TRS	0.71	< .001	< .001	0.63, 0.80
BD I compared to TRS	0.67	< .001	< .001	0.64, 0.71
BD II compared to TRS	0.54	< .001	< .001	0.50, 0.57
SABD compared to BD II	1.32	< .001	< .001	1.16, 1.50
BP I compared to BD II	1.25	< .001	< .001	1.16, 1.35
SABD compared to BD I	1.05	0.41	0.41	0.93, 1.18

TRS - treatment resistant schizophrenia, treated with clozapine, BDI - RDC bipolar disorder subtype I, BD II - RDC bipolar disorder type II, SABD-RDC bipolar schizoaffective disorder, RR – relative risk ratio PRS adjusted for 1st 10 PCs and genotyping platform 95% bootstrapped C.I. - 95% confidence intervals.

Figure 1: Probability of RDC bipolar subtype as a function of polygenic risk scores (PRS) for schizophrenia.

x-axis- standardized PRS in standard deviation units, SABD – schizoaffective bipolar type, BD I
Bipolar Disorder type I , BD II – Bipolar disorder type II.

Figure 2: Percentage of RDC bipolar subtype as a function of polygenic risk scores (PRS) for schizophrenia grouped by decile.

x-axis- deciles of PRS, SABD – schizoaffective bipolar type, BD I Bipolar Disorder type I , BD II – Bipolar disorder type II.

Figure 3: Relative Risk Ratios.
Height of bars represents Relative Risk Ratios for diagnosis or clinical feature compared with controls given 1 standard deviaton increase for schizophrenia polygenic score (PRS). Error Bars represent bootstrapped 95% confidence intervals. SABD – RDC schizoaffective bipolar type; , BD I – RDC bipolar disorder type I; BD II – RDC bipolar disorder type II: LEP – Lifetime Ever occurrence of psychosis within bipolar disorder; Low/High LMI – lifetime occurrence of Mood incongruence dichotomised as low or high within in those with psychotic forms of Bipolar Disorder